• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 16th May 2022

Open Source Modelling: From Ideas to Action

OHE’s Chris Sampson is currently Chair of the ISPOR Open Source Models Special Interest Group (SIG). The SIG recently published their first journal article in Value in Health and will be delivering a Forum at this week’s ISPOR conference. In…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Open-Source_Adobe_Siarhei-scaled-1

OHE’s Chris Sampson is currently Chair of the ISPOR Open Source Models Special Interest Group (SIG). The SIG recently published their first journal article in Value in Health and will be delivering a Forum at this week’s ISPOR conference. In this blog post, Chris provides some background to the work and an invitation to get involved.

OHE’s Chris Sampson is Chair of the ISPOR Open Source Models Special Interest Group (SIG). The SIG recently published its first journal article in Value in Health and will be delivering a Forum at this week’s ISPOR conference. In this blog post, Chris provides some background to the work and an invitation to get involved.

Cost-effectiveness modelling has become a central part of health technology assessment (HTA). It now makes up a large proportion of the work conducted by people who call themselves health economists. Despite the importance and influence of this kind of research, it is often seen as a black box by decision-makers. What’s more, researchers often have to reinvent models that other researchers have already developed to tackle similar decision problems.

Transparency has long been recognised as a cornerstone of science. Transparent research practices enable replication, validation, and scrutiny, all of which contribute to knowledge generation. When it comes to health economics and outcomes research – and decision modelling specifically – there are numerous ways in which our research might be more or less transparent. A few years ago, I and some colleagues outlined the role of different manifestations of transparency and how they relate to one another. One example that we discussed is open source modelling. Open source modelling is about making the underlying analysis script freely available to researchers, who might borrow and adapt the methods in part or in full for their own purposes.

The potential benefits of open source modelling have been discussed at length at numerous meetings in recent years. And on the whole, researchers have written favourably about the prospects of open source modelling. It’s becoming a popular idea. Yet, open source cost-effectiveness models are still few and far between. Though researchers report their intent to adopt open source modelling practices, we don’t see it happening.

This is why we created the ISPOR Open Source Models (OSM) Special Interest Group (SIG). The OSM SIG was the brainchild of Renée Arnold, with whom I developed the SIG and became the first Chair-Elect (and now Chair). One of the first things we wanted to do was to build an understanding of why open source modelling isn’t more widespread, despite indications of support from the research community. For this purpose, we surveyed ISPOR members.

The results of our survey were recently published in Value in Health. Across 230 respondents, both academia and industry were well represented. Unsurprisingly, the support for open source modelling was reiterated by this sample, but we were also able to find out more about the perceived barriers to open source modelling. For instance, legal concerns and secure data sharing were cited as key barriers. And what might cause a shift in practice? Many respondents took advantage of the free-text part of our survey to highlight the potential value of HTA agencies mandating or otherwise supporting open source practices. We can still learn more about stakeholders’ perspectives on open source modelling – especially from decision-makers – but our study could inform the development of new initiatives that might incentivise the adoption of open source practices.

This week sees the return of an in-person ISPOR conference in the US, the first since 2019. Several members of the OHE team will be there, and the OSM SIG has organised a Forum session titled Open Source In Precision Medicine: The Perfect Fit? Our goal with this session is to get real. We’ll discuss applied examples of open source modelling in precision medicine and consider whether open source practices are especially valuable in this context. Sometimes, open source modelling is seen as complicated and technical, while decision modelling in precision medicine is often necessarily so. Does this make them perfect bedfellows? If you’re attending ISPOR in person, please come and join our discussion.

Even if you aren’t attending the ISPOR conference, there are other opportunities to engage with this topic and with the SIG. Next month, we’ll be hosting our latest (virtual) journal club meeting. Our guest will be Koen Degeling, who will be discussing an open source discrete event simulation for colorectal cancer using real-world data. To attend this journal club and keep up to date with future activities, join our SIG.

 

Related research

Pouwels, X.G.L.V., Sampson, C.J., Arnold, R.J.G., On behalf of the Open Source Models Special Interest Group, 2022. Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. Value in Health, 25(4), pp.473–479. 10.1016/j.jval.2021.10.001.

Sampson, C.J., Arnold, R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F. and Wrightson, T., 2019. Transparency in Decision Modelling: What, Why, Who and How? PharmacoEconomics, 37(11), pp.1355–1369. 10.1007/s40273-019-00819-z.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • External Publications

Related Insights

HealthData&Stats_AdobeStock_168196575_landscape
  • Insight
  • August 2022

Improving the Measurement of Valued Output in Primary Care in England

Read more
Good and Broken Light Bulb
  • Insight
  • July 2022

Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly

Read more
NHSFinance_Adobe_ink-drop-scaled-1
  • Insight
  • June 2022

The State of Play for Cost-effectiveness Thresholds

Read more
Sleepio_Adobe_montblanca-e1673970227875
  • Insight
  • May 2022

Sleepio: Lessons from the Frontier of Digital Therapeutics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!